Biotech News

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.2026-06-25 13:46 ESTCommercial

MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the 25 th Annual

Open original release

Related news

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-06-25 13:46 EST

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

View all latest news

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-06-26 16:24 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-06-26 16:24 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-06-26 16:24 EST

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

MISTMilestone Pharmaceuticals Inc.2026-06-26 16:24 EST

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

MISTMilestone Pharmaceuticals Inc.2026-06-26 16:24 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States